2025
Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study.
Daver N, Kontro M, Rimpiläinen J, Pyörälä M, Siitonen T, Myllymäki M, Zeidner J, Witherall R, Searle E, Bono P, Berns D, Aakko S, Hollmen M, Zeidan A, Stein A. Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study. Journal Of Clinical Oncology 2025, 43: 6513-6513. DOI: 10.1200/jco.2025.43.16_suppl.6513.Peer-Reviewed Original ResearchDose-limiting toxicityMedian overall survivalMDS patientsOverall response rateDose escalationHR-MDSCLEVER-1Bone marrowRevised International Prognostic Scoring SystemDose-limiting toxicity periodMedian overall survival estimatesInternational Prognostic Scoring SystemNo dose limiting toxicitiesTreatment-emergent adverse eventsSimon 2-stage designBayesian optimal intervalBM immune microenvironmentRegimen of azacitidinePhase 1/2 studyPrimary refractory diseaseVascular endothelial receptor-1Prognostic scoring systemSafety follow-upOverall survival estimatesHigher-riskForecasting optimal treatments in relapsed/refractory mature T‐ and NK‐cell lymphomas: A global PETAL Consortium study
Sorial M, Han J, Koh M, Boussi L, Li S, Duan R, Lu J, Lei M, MacVicar C, Freydman J, Malespini J, Aniagboso K, McCabe S, Peng L, Singh S, Iwasaki M, Eche‐Ugwu I, Gabler J, Turizo M, Garg A, Disciullo A, Chopra K, Ford J, Lenart A, Nwodo E, Barnes J, Koh M, Miranda E, Chiattone C, Stuver R, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim J, Cho J, Eipe T, Shet T, Epari S, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince H, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al‐Mansour M, Cabrera M, Ku A, Bhagat G, Ma H, Sawas A, Kariya K, Bhanushali F, Meharwal A, Mistry D, Kosovsky M, Yeterian M, O'Connor O, Marchi E, Shen C, Shah D, Jain S. Forecasting optimal treatments in relapsed/refractory mature T‐ and NK‐cell lymphomas: A global PETAL Consortium study. British Journal Of Haematology 2025, 206: 1664-1677. PMID: 40310502, PMCID: PMC12167149, DOI: 10.1111/bjh.20063.Peer-Reviewed Original ResearchConceptsT-cell lymphomaCytotoxic chemotherapySmall molecule inhibitorsEpigenetic modifiersAngioimmunoblastic T-cell lymphomaPrimary refractory diseaseNK-cell lymphomasHigh-risk groupTransplant consolidationOverall survivalRefractory diseaseNK cellsPrognostic indexT cellsIdeal therapyMature TOptimal treatmentLymphomaGlobal cohortTreatment sequenceMolecule inhibitorsPatientsThird lineConsortium studyTreatmentGlobal outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
Han J, Koh M, Boussi L, Sorial M, McCabe S, Peng L, Singh S, Eche-Ugwu I, Gabler J, Turizo M, MacVicar C, Garg A, Disciullo A, Chopra K, Lenart A, Nwodo E, Barnes J, Koh M, Miranda E, Chiattone C, Stuver R, Horwitz S, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim J, Cho J, Eipe T, Shet T, Sridhar E, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince H, Hamouche R, Murdashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al-Mansour M, Ford J, Cabrera M, Ku A, Bhagat G, Ma H, Sawas A, Kariya K, Iwasaki M, Bhanushali F, O’Connor O, Marchi E, Shen C, Shah D, Jain S. Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium. Blood Advances 2025, 9: 583-602. PMID: 39481087, PMCID: PMC11821408, DOI: 10.1182/bloodadvances.2024014674.Peer-Reviewed Original ResearchNK-cell lymphomasOverall survivalMature T cellsALK-ALCLNK cellsT cellsAssociated with 3-year OSTiming of second-line treatmentSuperior median overall survivalMedian overall survivalPrimary refractory diseaseProgression-free survivalInternational retrospective cohort studySecond-line treatmentEfficacy of novel drugsIdentified several independent predictorsRetrospective cohort studyR/R lymphomaExtranodal sitesPTCL-NOSIntermediate-riskCytotoxic chemotherapyHistological subtypesRefractory diseaseRelapsed lymphoma
2024
Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study
Kontro M, Stein A, Pyörälä M, Rimpiläinen J, Siitonen T, Rannikko J, Mickos J, Turpin R, Hakoniemi M, Berns B, Aakko S, Pawlitzky I, Hollmén M, Zeidan A, Daver N. Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study. Blood 2024, 144: 4265. DOI: 10.1182/blood-2024-206804.Peer-Reviewed Original ResearchMedian overall survival estimatesMyelodysplastic syndrome patientsTreatment-emergent adverse eventsMyelodysplastic syndromeBone marrowMarrow CRStable diseaseHematologic improvementPartial responseCLEVER-1HLA-DROutcome of high-risk myelodysplastic syndromeHuman leukocyte antigen-DR isotypePhase 1 dose-escalationResponse of stable diseaseAllogeneic stem cell transplantationHigh-risk myelodysplastic syndromeHigher-risk myelodysplastic syndromesSimon 2-stage designTreatment of myelodysplastic syndromesResponse rateBayesian optimal intervalMedian overall survivalPrimary refractory diseaseRefractory myelodysplastic syndrome
2022
Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Badar T, Atallah E, Saliba A, Shallis R, Stahl M, Bewersdorf J, De Camargo Correia G, Patel A, Abaza Y, Murthy S, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kota V, Dinner S, Goldberg A, Litzow M. Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood 2022, 140: 6058-6060. DOI: 10.1182/blood-2022-163795.Peer-Reviewed Original ResearchPredictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. Journal Of Hematology & Oncology 2022, 15: 96. PMID: 35842643, PMCID: PMC9287914, DOI: 10.1186/s13045-022-01316-1.Peer-Reviewed Original ResearchConceptsMarginal zone lymphomaRefractory marginal zone lymphomaMulticenter cohort studyPrimary refractory diseaseOverall response rateStable diseaseCohort studyComplex cytogeneticsRefractory diseaseFirst-line therapyHigh-risk subsetType of therapyProgression of diseaseInferior OSInferior PFSMedian PFSPartial responsePredictive factorsExperimental therapiesStudy populationEligibility criteriaClinical practicePatientsResponse rateIbrutinib
2019
Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort
Sethi T, Kovach A, Mason E, Chen H, Moyo T, Oluwole O, Morgan D, Reddy N. Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort. Blood 2019, 134: 4100. DOI: 10.1182/blood-2019-129634.Peer-Reviewed Original ResearchOverall response rateProgression-free survivalDiffuse large B-cell lymphomaLarge B-cell lymphomaCombination of nivolumabDose-escalation cohortsNon-GCB DLBCLPrimary refractory diseaseB-cell lymphomaOverall survivalDay 1Prior linesRefractory diseaseCell lymphomaNon-germinal center diffuse large B-cell lymphomaSingle-arm open-label studyResponse rateAutologous stem cell transplantCommon grade 3/4 toxicitiesMedian progression-free survivalNon-germinal centre DLBCLAnti-PD-1 antibodyDiffuse large B-cell lymphoma patientsLarge B-cell lymphoma patientsCAR T-cell therapyCell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype
Montanari F, Deng C, Sawas A, Lue J, Marchi E, Radeski D, Cheng B, Bhagat G, O'Connor O. Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype. Blood 2019, 134: 2909. DOI: 10.1182/blood-2019-131841.Peer-Reviewed Original ResearchPost-transplant lymphoproliferative disorderDiffuse large B-cell lymphomaMonomorphic post-transplant lymphoproliferative disorderProgression-free survivalMedian progression-free survivalOverall survivalR-CHOPR-EPOCHGerminal centersCell of originImmunosuppressive therapyEBV infectionLymphoproliferative disordersTerms of PFSBetter progression-free survivalDLBCL subtypesCommon first-line therapySeattle GeneticsDiffuse large B-cell lymphoma (DLBCL) subtypeLarge B-cell lymphomaMonths-24 yearsComplete response rateMedian overall survivalPrimary refractory diseaseFirst-line therapyOutcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry
Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. Acta Haematologica 2019, 143: 40-50. PMID: 31315113, DOI: 10.1159/000500666.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaFront-line therapyComplete responseRelapsed diseaseT-cell lymphomaRefractory patientsInitial treatmentPrimary refractoryOverall survivalPeripheral T-cell lymphoma patientsResponse/stable diseaseT-cell lymphoma patientsAggressive T-cell lymphomaSingle-agent regimensDays of enrollmentObjective response ratePrimary refractory diseaseSecond-line settingSecond-line therapyActive single agentProspective outcome dataSingle-agent therapyLonger overall survivalUnmet medical needGood response
2016
Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue
Hui L, von Keudell G, Wang R, Zeidan A, Gore S, Ma X, Davidoff A, Huntington S. Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue. Blood 2016, 128: 1188. DOI: 10.1182/blood.v128.22.1188.1188.Peer-Reviewed Original ResearchAutologous stem cell transplantationReconstructed individual patient dataIncremental cost-effectiveness ratioR Hodgkin lymphomaIndividual patient dataHodgkin's lymphomaActive surveillanceOverall survivalHealth care costsHL progressionHL recurrenceHealthcare costsCare costsHigh-risk Hodgkin lymphomaSignificant health care costsDouble-blind trialPatient dataUse of BVFirst-line therapyHigh-dose chemotherapyPrimary refractory diseaseProgression-free survivalStem cell rescueLong-term followStem cell transplantation
2014
The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma)
Radeski D, Hoehn D, Montanari F, Alobeid B, Zhang Y, Amengual J, Sawas A, Deng C, O’Connor O, Bhagat G. The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma). Blood 2014, 124: 4449. DOI: 10.1182/blood.v124.21.4449.4449.Peer-Reviewed Original ResearchMonomorphic post-transplant lymphoproliferative disorderPost-transplant lymphoproliferative disorderProgression-free survivalProlonged progression-free survivalCell of originAdvanced stage diseaseExtra-nodal involvementPrimary refractory diseaseFirst-line therapyR-CHOPR-EPOCHOverall survivalRituximab monotherapyLine therapyNodal involvementRefractory diseaseStage diseaseClinical presentationLymphoproliferative disordersTreatment regimensB cellsBone marrow/stem cell transplantationAutologous stem cell transplantCommon first-line therapyNon-germinal center B-cell
2011
Hodgkin’s Lymphoma Cell Lines Have up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, An IL-3Rα Targeted Drug,
Diefenbach C, Sabado R, Brooks C, Baquero-Buitrago J, Cruz C, Vengco I, Montanari F, Marchi E, Scotto L, Cirrito T, Bergstein I, O'Connor O. Hodgkin’s Lymphoma Cell Lines Have up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, An IL-3Rα Targeted Drug,. Blood 2011, 118: 3737. DOI: 10.1182/blood.v118.21.3737.3737.Peer-Reviewed Original ResearchHodgkin Reed-Sternberg cellsSL-401CD123 expressionHodgkin's lymphomaComplete responseTreatment strategiesLymphoma cell linesMyeloid leukemiaCell linesAutologous stem cell transplantMalignant Hodgkin Reed-Sternberg (HRS) cellsCell viabilityPrimary refractory diseaseRefractory Hodgkin lymphomaSecond-line chemotherapySecond-line therapyHigh expressionEffective therapeutic optionStem cell transplantReceptor α expressionAcute myeloid leukemiaChronic myeloid leukemiaClassical Hodgkin lymphomaPotential treatment strategyNovel treatment strategies
1991
Treatment for Acute Myelocytic Leukemia With Allogeneic Bone Marrow Transplantation Following Preparation With BuCy2
Copelan E, Biggs J, Thompson J, Crilley P, Szer J, Klein J, Kapoor N, Avalos B, Cunningham I, Atkinson K, Downs K, Harmon G, Daly M, Brodsky I, Bulova S, Tutschka P. Treatment for Acute Myelocytic Leukemia With Allogeneic Bone Marrow Transplantation Following Preparation With BuCy2. Blood 1991, 78: 838-843. DOI: 10.1182/blood.v78.3.838.838.Peer-Reviewed Original ResearchLeukemia-free survivalAcute myelocytic leukemiaAllogeneic bone marrow transplantationBone marrow transplantationMarrow transplantationMyelocytic leukemiaActuarial probability of relapseDecreased LFSFrench-American-British classificationBusulfan 4 mg/kgDiagnosis to transplantPrimary refractory diseaseTotal body irradiationProbability of relapseAdvanced disease phaseOne-hundredActuarial probabilityPreparative regimenHLA-identicalRemission patientsBody irradiationPrognostic factorsRefractory diseaseHematological disordersRelapse
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply